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Human Gyrovirus  
in Healthy Blood 
Donors, France
To the Editor: Gyroviruses 
(GyVs) are naked, single-stranded 
DNA viruses that were described in 
chickens in 1979 (1). Chicken anemia 
virus (CAV), initially the sole mem-
ber of the genus Gyrovirus (family 
Circoviridae), possesses a genome of 
≈2.3 kb, containing 3 major partially 
overlapping open reading frames, vi-
ral proteins [VP] 1–3, and a short un-
translated region (1). For >30 years, 
this virus, which was responsible for 
severe anemia and increased death 
rates in young chickens, was consid-
ered to have an extremely low genetic 
diversity and to be specific to this ani-
mal host. In 2011, however, sequence-
independent molecular protocols en-
abled the characterization of highly 
divergent, GyV-related sequences in 
human and chicken biological sam-
ples. Human GyV 1 (HGyV1), avian 
GyV 2, and GyV3 sequences were 
identified from human skin, chicken 
blood, and human feces, respectively 
(2–4). These genomes harbor a genetic 
organization similar to CAV, despite a 
high genetic divergence (49%–65%).
One study described the detection 
of GyVs in HIV-positive patients and 
kidney transplant recipients (0.7% and 
6%, respectively) (5), but these viruses 
had not been identified in blood sam-
ples from healthy persons. We investi-
gated the presence of HGyV DNA in 
352 blood samples from healthy blood 
donors in France (mean age 39 years; 
185 men; M:F ratio 1:1.11). 
Plasma samples were prepared as 
described (6), and 1-mL aliquots were 
used for nucleic acids extraction (Mag-
NA pure LC; Roche Diagnostics, Mey-
lan, France). HGyV DNA was detected 
by using 2 systems in separate real-time 
TaqMan amplification assays (StepOne 
Plus; Applied Biosystems, Courta-
boeuf, France). The first detection assay 
(VP1 gene) was described previously 
(HGyV-rtFP/HGyV-rtRP primers, 
HGyV-rtP probe, 72 nt) (5). The sec-
ond assay was designed following the 
analysis of available HGyV sequences 
(Figure): sense primer HGyVsPBs 
5′-GCTAAGACTGTRACATGGC-3′, 




RA-3′. This assay targets the VP2 gene 
of the viral genome, with an expected 
length of 118–115 bp, depending on the 
reference sequence considered. 
Amplification reactions were per-
formed by using 10% of extracted ma-
terial with the TaqMan Fast Universal 
PCR Kit (Applied Biosystems) in a 
final volume of 20 μL. Cycling condi-
tions for both assays were 95°C for 20 
s, followed by 50 cycles of 95°C for 
1 s and 60°C for 20 s. The sensitiv-
ity of TaqMan assays was estimated to 
be 10 copies of HGyV DNA by using 
dilutions of a synthetic template. Each 
amplification product was subjected to 
additional agarose gel electrophoresis 
to help eliminate potential false-nega-
tive real-time PCR results.
Among the 352 plasma samples 
tested, 3 (0.85%) resulted in a positive 
signal by using our in-house real-time 
detection assay; no positive signal was 
identified by using the other system 
tested. When the tests were repeated, 
identical results were obtained. No 
additional amplicons were identifi-
able after agarose gel analysis. HGyV 
DNA titers in the 3 positive samples 
were low (<500 copies/mL plasma). 
Positive blood samples originated 
from 1 woman (age 44) and 2 men 
(ages 29 and 39). No biological or se-
rologic marker evaluated for routine 
blood donor screening in France was 
associated with these donations. 
Partial HGyV sequences obtained 
were cloned and sequenced (7 clones 
each). All sequences characterized 
clustered with HGyV1 sequences, ex-
hibiting either 100% nucleotide iden-
tity or 1 point mutation (correspond-
ing to a nonsynonymous substitution, 
ala →thr) (Figure). No intragenetic 
diversity was identified.
Our results demonstrate that re-
cently discovered HGyVs are detect-
able in blood of healthy persons. The 
low prevalence (0.85%) suggests, 
however, that the virus is infrequent-
ly found in the general population in 
France. A study from Italy of HGyVs 
in blood from healthy donors did not 
detect such viruses (5). This result 
may be linked to the small number of 
samples tested (n = 50) or to the use 
of a nonoptimized detection system 
designed on the basis of HGyV1 se-
quences only; moreover, the possibil-
ity that the VP1 and VP2 amplified 
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Figure.	Alignment	of	partial	sequences	of	human	gyroviruses	(HGyVs)	from	healthy	blood	donors,	France.	Point	mutation	corresponding	
to	 a	 nonsynonymous	 substitution	 is	 in	 boldface	 (13F1	 isolate).	 Reference	 sequences	 and	 GenBank	 accession	 nos.:	 HGyV1-915,	




regions would be conserved differ-
ently must be considered.
It is probable that subsequent 
sequences of HGyVs remain to be 
identified in human blood. A recent 
study reported the characterization 
of a highly divergent GyV sequence 
(GyV4) in human fecal samples and 
chicken meat (7); as with avian GyV2 
and GyV3, further research is needed 
to determine whether this variant rep-
licates in the human body or is solely 
ingested in food and passively excret-
ed. A better knowledge of the genetic 
diversity of these newly discovered 
viruses will enable development of 
improved molecular detection sys-
tems and their subsequent use in epi-
demiologic studies involving diverse 
human cohorts.
The potential clinical importance 
of HGyVs remains to be clarified. Al-
though infection with CAV in birds 
is frequently associated with clini-
cal signs and disease, the presence of 
HGyVs in immunocompromised or 
immunocompetent humans does not 
appear to be correlated with visible 
symptoms. Further studies of the natu-
ral history and distribution of HGyVs 
in human hosts are needed.
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Vibrio cholerae  




To the Editor: Vibrio cholerae 
O1, a causative agent of cholera, was 
classified into 2 biotypes, classical and 
El Tor (1). However, accumulating 
evidence suggests that atypical El Tor 
V. cholerae, which possesses traits of 
both classical and El Tor biotypes, has 
replaced the seventh pandemic pro-
totypic El Tor V. cholerae worldwide 
in recent years. Cholera outbreaks 
in Thailand during 2007–2010 were 
caused by atypical El Tor isolates car-
rying the classical type cholera toxin 
gene (2). Epidemiologic surveys in a 
Thailand–Myanmar border area during 
2008–2012 yielded more than 500 iso-
lates of V. cholerae O1. We identified 
an isolate that possessed the typical El 
Tor type cholera toxin gene (genotype 
3) and designated it MS6 (later as-
signed strain number DMST28216). It 
does not belong to either the seventh 
pandemic prototypic biotype identified 
in 1961 or the group of atypical El Tor 
strains found during 1991–present (3).
MS6 was isolated from stool 
samples from a 26-year-old woman 
(migrant worker) from Myanmar who 
had been admitted to Mae Sot General 
Hospital in Tak Province, Thailand, 
for 3 days with vomiting, watery diar-
rhea, nausea, fever, and headache. The 
illness was considered mild to mod-
erate. Acute gastroenteritis was diag-
nosed on the basis of the symptoms 
and laboratory results. The key viru-
lence factors of V. cholerae O1 include 
cholera toxin (CTX), which is respon-
sible for profuse watery diarrhea, and 
a pilus colonization factor known as 
toxin-coregulated pilus (TCP). The 
virulence-related genes (ctxAB and 
tcpA) and the phage repressor gene 
(rstR) of MS6 had identical sequences 
to those of the seventh pandemic pro-
totypic El Tor V. cholerae O1 N16961 
strain. The isolate was found to be 
positive for enteric bacteria in the 
Voges-Proskauer test and resistant to 
polymyxin B (50 units). We further 
investigated 2 gene clusters, Vibrio 
seventh pandemic island I (VSP-I) 
and II (VSP-II), associated with the 
seventh pandemic strains and absent 
in classical and pre–seventh pandemic 
strains (4–7). The common genes on 
the VSP-I island in N16961, including 
VC0175, VC0178, VC0180, VC0181, 
and VC0183, were detected by PCR 
(8) in MS6 but were lacking in VSP-
II; 26.9 kb of VSP-II was originally 
found in N16961. Moreover, PCR 
analysis showed that the isolate did not 
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